Early referral recommendation for newly diagnosed rheumatoid arthritis: evidence based development of a clinical guide

…, FC Breedveld, M Dougados, JR Kalden… - Annals of the …, 2002 - ard.bmj.com
Background: Effective treatment of active rheumatoid arthritis (RA) requires early diagnosis
and early disease modifying antirheumatic drug (DMARD) treatment to have an impact on …

SLE—a disease of clearance deficiency?

…, US Gaipl, S Franz, A Sheriff, RE Voll, JR Kalden… - …, 2005 - academic.oup.com
Systemic lupus erythematosus (SLE) is a multifactorial disease and its pathogenesis and
precise aetiology remain unknown. Under physiological conditions, neither apoptotic nor …

The balance of Th1/Th2 cytokines in rheumatoid arthritis

H Schulze-Koops, JR Kalden - Best practice & research Clinical …, 2001 - Elsevier
It has been suggested that rheumatoid inflammation is mediated by activated pro-inflammatory
T helper type I cells. In contrast, immunomodulatory T helper type 2 cells and their …

[HTML][HTML] Infliximab and methotrexate in the treatment of rheumatoid arthritis

…, DE Furst, FC Breedveld, JR Kalden… - … England Journal of …, 2000 - Mass Medical Soc
Background Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces
the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to …

Immunosuppressive effects of apoptotic cells

RE Voll, M Herrmann, EA Roth, C Stach, JR Kalden… - Nature, 1997 - nature.com
Apoptotic cell death is important in the development and homeostasis of multicellular organisms
1 and is a highly controlled means of eliminating dangerous, damaged or unnecessary …

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis

MJ Elliott, RN Maini, M Feldmann, JR Kalden, C Antoni… - The Lancet, 1994 - Elsevier
Tumour necrosis factor α (TNFα) is a critical inflammatory mediator in rheumatoid arthritis,
and may therefore be a useful target for specific immunotherapy. In support of this hypothesis, …

Therapeutic efficacy of multiple intravenous infusions of anti‐tumor necrosis factor α monoclonal antibody combined with low‐dose weekly methotrexate in rheumatoid …

RN Maini, FC Breedveld, JR Kalden… - … : Official Journal of …, 1998 - Wiley Online Library
Objective To evaluate the efficacy, pharmacokinetics, immunogenicity, and safety of multiple
infusions of a chimeric monoclonal anti‐tumor necrosis factor α antibody (cA2) (infliximab; …

Preliminary criteria for the classification of Sjögren's syndrome. Results of a prospective concerted action supported by the European Community

…, DA Isenberg, A Janin, JR Kalden… - … : Official Journal of …, 1993 - Wiley Online Library
Objective. Different sets of diagnostic criteria have been proposed for Sjögren's syndrome (SS),
but none have been validated with a large series of patients or in a multicenter study. We …

A simplified disease activity index for rheumatoid arthritis for use in clinical practice

JS Smolen, FC Breedveld, MH Schiff, JR Kalden… - …, 2003 - academic.oup.com
Objective. The objective of this study was to verify the usefulness of a simple disease activity
index (SDAI) for rheumatoid arthritis (RA). Methods. The SDAI is the numerical sum of five …

Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial

…, P Emery, E Keystone, M Schiff, JR Kalden… - Arthritis & …, 2004 - Wiley Online Library
… Clair, van der Heijde, Smolen, Maini, Bathon, Emery, Keystone, and Kalden have received
consultancies and/or honoraria from Centocor, Inc., totaling less than $10,000 per year. In …